Clinical Trial Update: TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating transarterial chemoembolization (TACE) combined with an anti-PD-1 antibody for advanced hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-PD-1 antibody

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED